Breastfeeding While Taking Lamivudine or Tenofovir Disoproxil Fumarate: A Review of the Evidence | Zendy

Stephan Ehrhardt | Zendy; Chan Xie | Zendy; Nan Guo | Zendy; Kenrad E. Nelson | Zendy; Chloe L. Thio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Breastfeeding While Taking Lamivudine or Tenofovir Disoproxil Fumarate: A Review of the Evidence

Author(s) -

Stephan Ehrhardt,

Chan Xie,

Nan Guo,

Kenrad E. Nelson,

Chloe L. Thio

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu798

Subject(s) - tenofovir , medicine , lamivudine , breastfeeding , virology , pediatrics , human immunodeficiency virus (hiv) , virus , hepatitis b virus

Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV). Due to its potency, high genetic barrier to resistance, and safety during pregnancy, TDF may be useful to prevent HBV transmission from mother to child, which is the leading cause of transmission globally. Despite the safety record of lamivudine and TDF in pregnancy, the labels for both of these drugs recommend against their use during breastfeeding. In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research